Skip to main content
SpringerLink
Log in

Personalized Radiation Oncology: Epidermal Growth Factor Receptor and Other Receptor Tyrosine Kinase Inhibitors

  • Chapter
  • First Online:
Molecular Radio-Oncology

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 198))

Abstract

Molecular biomarkers are currently evaluated in preclinical and clinical studies in order to establish predictors for treatment decisions in radiation oncology. The receptor tyrosine kinases (RTK) are described in the following text. Among them, the most data are available for the epidermal growth factor receptor (EGFR) that plays a major role for prognosis of patients after radiotherapy, but seems also to be involved in mechanisms of radioresistance, specifically in repopulation of tumour cells between radiotherapy fractions. Monoclonal antibodies against the EGFR improve locoregional tumour control and survival when applied during radiotherapy, however, the effects are heterogeneous and biomarkers for patient selection are warranted. Also other RTK´s such as c-Met and IGF-1R seem to play important roles in tumour radioresistance. Beside the potential to select patients for molecular targeting approaches combined with radiotherapy, studies are also needed to evluate radiotherapy adaptation approaches for selected patients, i.e. adaptation of radiation dose, or, more sophisticated, of target volumes.

G.S. Higgins, M. Krause: Equal contribution

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Abdollahi A et al (2005) Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med 201(6):925–935

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Abramsson A, Lindblom P, Betsholtz C (2003) Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest 112(8):1142–1151

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Adams TE et al (2000) Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci 57(7):1050–1093

    Article  CAS  PubMed  Google Scholar 

  • Aebersold DM et al (2001) Involvement of the hepatocyte growth factor/scatter factor receptor c-met and of Bcl-xL in the resistance of oropharyngeal cancer to ionizing. Int J Cancer 96(1):41–54

    Article  CAS  PubMed  Google Scholar 

  • Andrae J, Gallini R, Betsholtz C (2008) Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22(10):1276–1312

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ang KK et al (2002) Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62(24):7350–7356

    CAS  PubMed  Google Scholar 

  • Arcaro A (2013) Targeting the insulin-like growth factor-1 receptor in human cancer. Front Pharmacol 4:30

    Article  PubMed  PubMed Central  Google Scholar 

  • Arnaldez FI, Helman LJ (2012) Targeting the insulin growth factor receptor 1. Hematol Oncol Clin North Am 26(3):527–542

    Google Scholar 

  • Battegay EJ et al (1994) PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF beta-receptors. J Cell Biol 125(4):917–928

    Article  CAS  PubMed  Google Scholar 

  • Baumann M et al (2007) EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms. Radiother Oncol 83(3):238–248

    Article  CAS  PubMed  Google Scholar 

  • Bentzen SM et al (2005) Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol 23(24):5560–5567

    Article  CAS  PubMed  Google Scholar 

  • Bernhard EJ et al (2000) Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines. Cancer Res 60(23):6597–6600

    CAS  PubMed  Google Scholar 

  • Bhardwaj V et al (2012) C-Met inhibitor MK-8003 radiosensitizes c-Met-expressing non-small-cell lung cancer cells with radiation-induced c-Met-expression. J Thorac Oncol 7(8):1211–1217

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bokemeyer C et al (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27(5):663–671

    Article  CAS  PubMed  Google Scholar 

  • Bonner JA et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354(6):567–578

    Article  CAS  PubMed  Google Scholar 

  • Bonner JA et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11(1):21–28

    Article  CAS  PubMed  Google Scholar 

  • Burtness B, Bauman JE, Galloway T (2013) Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition. Lancet Oncol 14(8):e302–e309

    Article  CAS  PubMed  Google Scholar 

  • Cappuzzo F et al (2009) Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 27(10):1667–1674

    Article  PubMed  PubMed Central  Google Scholar 

  • Caudell JJ et al (2008) Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment. Int J Radiat Oncol Biol Phys 71(3):676–681

    Article  CAS  PubMed  Google Scholar 

  • Chakravarti A et al (2002) The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. Cancer Res 62(15):4307–4315

    CAS  PubMed  Google Scholar 

  • Chakravarti A et al. (2005a) Expression of the epidermal growth factor receptor and HER-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the radiation therapy oncology group. Int J Radiat Oncol Biol Phys 62(2):309–317

    Google Scholar 

  • Chakravarti A et al. (2005b) Immunohistochemically determined total epidermal growth factor receptor levels not of prognostic value in newly diagnosed glioblastoma multiforme: report from the radiation therapy oncology group. Int J Radiat Oncol Biol Phys 62(2)318–327

    Google Scholar 

  • Chinot OL et al (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370(8):709–722

    Article  CAS  PubMed  Google Scholar 

  • Chitnis MM et al. (2013) IGF-1R inhibition enhances radiosensitivity and delays double-strand break repair by both non-homologous end-joining and homologous recombination. Oncogene

    Google Scholar 

  • Chung EJ et al (2009) In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase. Clin Cancer Res 15(9):3050–3057

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Contessa JN et al (2006) Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation. Breast Cancer Res Treat 95(1):17–27

    Article  CAS  PubMed  Google Scholar 

  • De Bacco F et al (2011) Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J Natl Cancer Inst 103(8):645–661

    Article  PubMed  Google Scholar 

  • Dings RP et al (2007) Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res 13(11):3395–3402

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Duru N et al (2012) HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells. Clin Cancer Res 18(24):6634–6647

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Eberhard DA et al (2005) Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23(25):5900–5909

    Article  CAS  PubMed  Google Scholar 

  • Eicheler W et al (2005) Kinetics of EGFR expression during fractionated irradiation varies between different human squamous cell carcinoma lines in nude mice. Radiother Oncol 76(2):151–156

    Article  CAS  PubMed  Google Scholar 

  • Eriksen JG, Steiniche T, Overgaard J et al (2005) The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized DAHANCA 6 and 7 study. Radiother Oncol 74(2):93–100

    Article  CAS  PubMed  Google Scholar 

  • Fan S et al (1998) Scatter factor protects epithelial and carcinoma cells against apoptosis induced by DNA-damaging agents. Oncogene 17(2):131–141

    Article  CAS  PubMed  Google Scholar 

  • Fan S et al (2000) The cytokine hepatocyte growth factor/scatter factor inhibits apoptosis and enhances DNA repair by a common mechanism involving signaling through phosphatidyl inositol 3’ kinase. Oncogene 19(18):2212–2223

    Article  CAS  PubMed  Google Scholar 

  • Favelyukis S et al (2001) Structure and autoregulation of the insulin-like growth factor 1 receptor kinase. Nat Struct Biol 8(12):1058–1063

    Article  CAS  PubMed  Google Scholar 

  • Ferrara N et al (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3(5):391–400

    Article  CAS  PubMed  Google Scholar 

  • Fidler MJ et al (2012) Targeting the insulin-like growth factor receptor pathway in lung cancer: problems and pitfalls. Ther Adv Med Oncol 4(2):51–60

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Fokas E et al (2012) Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature. Cancer Res 72(1):239–248

    Article  CAS  PubMed  Google Scholar 

  • Gately K et al (2014) High coexpression of both EGFR and IGF1R correlates with poor patient prognosis in resected non-small-cell lung cancer. Clin Lung Cancer 15(1):58–66

    Article  CAS  PubMed  Google Scholar 

  • Gilbert MR et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370(8):699–708

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Goel S et al (2011) Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 91(3):1071–1121

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gross NJ (1977) Pulmonary effects of radiation therapy. Ann Intern Med 86(1):81–92

    Article  CAS  PubMed  Google Scholar 

  • Gurtner K et al (2011) Diverse effects of combined radiotherapy and EGFR inhibition with antibodies or TK inhibitors on local tumour control and correlation with EGFR gene expression. Radiother Oncol 99:323–330

    Article  CAS  PubMed  Google Scholar 

  • Gurtner K et al. (2013) EGFR-amplification correlates with response to combined treatment of fractionated irradiation and EGFR-inhibition in HNSCC tumour xenografts. In: 17th European Cancer conference (ECCO), Amsterdam, p 51

    Google Scholar 

  • Hirsch FR et al (2003) Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21(20):3798–3807

    Article  CAS  PubMed  Google Scholar 

  • Hirsch FR et al (2006) Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 24(31):5034–5042

    Article  CAS  PubMed  Google Scholar 

  • Homsi J, Daud AI (2007) Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control 14(3):285–294

    PubMed  Google Scholar 

  • Iwasa T et al (2009) Inhibition of insulin-like growth factor 1 receptor by CP-751,871 radiosensitizes non-small cell lung cancer cells. Clin Cancer Res 15(16):5117–5125

    Article  CAS  PubMed  Google Scholar 

  • Jeon YK et al (2006) Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer. Lung Cancer 54(3):387–398

    Article  PubMed  Google Scholar 

  • Johnson BE, Janne PA (2005) Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Cancer Res 65(17):7525–7529

    CAS  PubMed  Google Scholar 

  • Karapetis CS et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359(17):1757–1765

    Article  CAS  PubMed  Google Scholar 

  • Kleibeuker EA et al (2012) Combining angiogenesis inhibition and radiotherapy: a double-edged sword. Drug Resist Updat 15(3):173–182

    Article  CAS  PubMed  Google Scholar 

  • Koi L et al (2014) Radiolabeled anti-EGFR-antibody improves local tumor control after external beam radiotherapy and offers theragnostic potential. Radiother Oncol 110(2):362–369

    Article  CAS  PubMed  Google Scholar 

  • Kong DS et al (2009) Prognostic significance of c-Met expression in glioblastomas. Cancer 115(1):140–148

    Article  PubMed  Google Scholar 

  • Krause M, Baumann M (2008) Clinical biomarkers of kinase activity: examples from EGFR inhibition trials. Cancer Metastasis Rev 27(3):387–402

    Article  CAS  PubMed  Google Scholar 

  • Lara PC et al (2011) IGF-1R expression predicts clinical outcome in patients with locally advanced oral squamous cell carcinoma. Oral Oncol 47(7):615–619

    Article  CAS  PubMed  Google Scholar 

  • Ledel F et al (2014) HER3 expression in patients with primary colorectal cancer and corresponding lymph node metastases related to clinical outcome. Eur J Cancer 50(3):656–662

    Article  CAS  PubMed  Google Scholar 

  • Lee CM et al (2005) Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix. Gynecol Oncol 99(2):415–421

    Article  CAS  PubMed  Google Scholar 

  • Li M, Jendrossek V, Belka C (2007) The role of PDGF in radiation oncology. Radiat Oncol 2:5

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Linge et al (2016) Clin Cancer Res, epub doi: 10.1158/1078-0432.CCR-15-1990

    Google Scholar 

  • Lipton A et al (2013) HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer. Breast Cancer Res Treat 141(1):43–53

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lloret M et al (2008) MVP expression is related to IGF1-R in cervical carcinoma patients treated by radiochemotherapy. Gynecol Oncol 110(3):304–307

    Article  CAS  PubMed  Google Scholar 

  • Ludovini V et al (2013) Concomitant high gene copy number and protein overexpression of IGF1R and EGFR negatively affect disease-free survival of surgically resected non-small-cell-lung cancer patients. Cancer Chemother Pharmacol 71(3):671–680

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ma PC et al (2003) c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 63(19):6272–6281

    CAS  PubMed  Google Scholar 

  • Ma PC et al (2008) Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer 47(12):1025–1037

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Macaulay VM et al (2001) Downregulation of the type 1 insulin-like growth factor receptor in mouse melanoma cells is associated with enhanced radiosensitivity and impaired activation of Atm kinase. Oncogene 20(30):4029–4040

    Article  CAS  PubMed  Google Scholar 

  • Marioni G et al (2011) Laryngeal carcinoma prognosis after postoperative radiotherapy correlates with CD105 expression, but not with angiogenin or EGFR expression. Eur Arch Otorhinolaryngol 268(12):1779–1787

    Article  PubMed  Google Scholar 

  • Maulik G et al (2002) Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev 13(1):41–59

    Article  CAS  PubMed  Google Scholar 

  • Moreno-Acosta P et al (2012) IGF1R gene expression as a predictive marker of response to ionizing radiation for patients with locally advanced HPV16-positive cervical cancer. Anticancer Res 32(10):4319–4325

    CAS  PubMed  Google Scholar 

  • Nicholson RI, Gee JM, Harper ME (2001) EGFR and cancer prognosis. Eur J Cancer 37(Suppl 4):9–15

    Article  Google Scholar 

  • Olsson AK et al (2006) VEGF receptor signalling—in control of vascular function. Nat Rev Mol Cell Biol 7(5):359–371

    Article  CAS  PubMed  Google Scholar 

  • Organ SL, Tsao MS (2011) An overview of the c-MET signaling pathway. Ther Adv Med Oncol 3(1 Suppl):S7–S19

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ou SH (2011) Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. Drug Des Devel Ther 5:471–485

    Article  PubMed  PubMed Central  Google Scholar 

  • Peretz S et al (2001) ATM-dependent expression of the insulin-like growth factor-I receptor in a pathway regulating radiation response. Proc Natl Acad Sci U.S.A. 98(4):1676–1681

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Petersen C et al (2003) Proliferation and micromilieu during fractionated irradiation of human FaDu squamous cell carcinoma in nude mice. Int J Radiat Biol 79(7):469–477

    Article  CAS  PubMed  Google Scholar 

  • Ponzetto C et al (1994) A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 77(2):261–271

    Article  CAS  PubMed  Google Scholar 

  • Riesterer O et al (2011) Combination of anti-IGF-1R antibody A12 and ionizing radiation in upper respiratory tract cancers. Int J Radiat Oncol Biol Phys 79(4):1179–1187

    Article  CAS  PubMed  Google Scholar 

  • Risau W et al (1992) Platelet-derived growth factor is angiogenic in vivo. Growth Factors 7(4):261–266

    Article  CAS  PubMed  Google Scholar 

  • Rochester MA et al (2005) Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer. Cancer Gene Ther 12(1):90–100

    Article  CAS  PubMed  Google Scholar 

  • Salomon DS et al (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19(3):183–232

    Article  CAS  PubMed  Google Scholar 

  • Scagliotti GV, Novello S, von Pawel J (2013) The emerging role of MET/HGF inhibitors in oncology. Cancer Treat Rev 39(7):793–801

    Article  CAS  PubMed  Google Scholar 

  • Shelton JG et al (2004) Synergy between PI3K/Akt and Raf/MEK/ERK pathways in IGF-1R mediated cell cycle progression and prevention of apoptosis in hematopoietic cells. Cell Cycle 3(3):372–379

    Article  CAS  PubMed  Google Scholar 

  • Soliman M et al (2013) GTV differentially impacts locoregional control of non-small cell lung cancer (NSCLC) after different fractionation schedules: subgroup analysis of the prospective randomized CHARTWEL trial. Radiother Oncol 106(3):299–304

    Article  PubMed  Google Scholar 

  • Tada H et al (2003) Increased binding and chemotactic capacities of PDGF-BB on fibroblasts in radiation pneumonitis. Radiat Res 159(6):805–811

    Article  CAS  PubMed  Google Scholar 

  • Temam S et al (2007) Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 25(16):2164–2170

    Article  CAS  PubMed  Google Scholar 

  • Tsao MS et al (2005) Erlotinib in lung cancer—molecular and clinical predictors of outcome. N Engl J Med 353(2):133–144

    Article  CAS  PubMed  Google Scholar 

  • Turner BC et al (1997) Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res 57(15):3079–3083

    CAS  PubMed  Google Scholar 

  • Valenciano A et al (2012) Role of IGF-1 receptor in radiation response. Transl Oncol 5(1):1–9

    Article  PubMed  PubMed Central  Google Scholar 

  • Welsh JW et al (2009) The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells. Radiat Oncol 4:69

    Article  PubMed  PubMed Central  Google Scholar 

  • Wheeler S et al (2012) Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma. Clin Cancer Res 18(8):2278–2289

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Xue Y et al (2012) PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells. Nat 18(1):100–110

    Article  CAS  Google Scholar 

  • Yavari K et al (2010) SiRNA-mediated IGF-1R inhibition sensitizes human colon cancer SW480 cells to radiation. Acta Oncol 49(1):70–75

    Article  CAS  PubMed  Google Scholar 

  • Yee D (2012) Insulin-like growth factor receptor inhibitors: baby or the bathwater? J Natl Cancer Inst 104(13):975–981

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yi S, Tsao MS (2000) Activation of hepatocyte growth factor-met autocrine loop enhances tumorigenicity in a human lung adenocarcinoma cell line. Neoplasia 2(3):226–234

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zha J, Lackner MR (2010) Targeting the insulin-like growth factor receptor-1R pathway for cancer therapy. Clin Cancer Res 16(9):2512–2517

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gray Laboratories, Department of Oncology, Cancer Research UK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Old Road Campus Research Building, Oxford, UK

    Geoff S Higgins & W Gillies McKenna

  2. OncoRay - National Center for Radiation Research in Oncology (NCRO), Carl Gustav Carus Faculty of Medicine, University Hospital, Technische Universität Dresden and Helmholtz-Zentrum Dresden—Rossendorf, Dresden, Germany

    Mechthild Krause & Michael Baumann

  3. German Cancer Consortium (DKTK) Dresden, German Cancer Research Center (DKFZ), Heidelberg, Germany

    Mechthild Krause & Michael Baumann

  4. Helmholtz-Zentrum Dresden—Rossendorf, Insititute of Radiooncology, Dresden, Germany

    Mechthild Krause & Michael Baumann

  5. Department of Radiation Oncology, Carl Gustav Carus Faculty of Medicine, University Hospital, Technische Universität Dresden, Dresden, Germany

    Mechthild Krause & Michael Baumann

Authors
  1. Geoff S Higgins
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mechthild Krause
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W Gillies McKenna
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael Baumann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mechthild Krause .

Editor information

Editors and Affiliations

  1. Department of Radiation Oncology, University of Technology, Dresden, Germany

    Michael Baumann

  2. Klinik und Poliklinik für Stra, Medizinische Fakultät und Univ, Dresden, Germany

    Mechthild Krause

  3. University of Technology, Dresden, Germany

    Nils Cordes

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Higgins, G.S., Krause, M., McKenna, W.G., Baumann, M. (2016). Personalized Radiation Oncology: Epidermal Growth Factor Receptor and Other Receptor Tyrosine Kinase Inhibitors. In: Baumann, M., Krause, M., Cordes, N. (eds) Molecular Radio-Oncology. Recent Results in Cancer Research, vol 198. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-49651-0_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-49651-0_5

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-49649-7

  • Online ISBN: 978-3-662-49651-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation